| Literature DB >> 35093012 |
Tim Litwin1,2,3, Jens Timmer4,5,6, Mathias Berger7, Andreas Wahl-Kordon8, Matthias J Müller9,10, Clemens Kreutz11,4,6.
Abstract
BACKGROUND: Surveillance testing within healthcare facilities provides an opportunity to prevent severe outbreaks of coronavirus disease 2019 (COVID-19). However, the quantitative impact of different available surveillance strategies and their potential to decrease the frequency of outbreaks are not well-understood.Entities:
Keywords: Agent-based model; COVID-19; Infectious disease surveillance; Long-term care; Point-of-care testing
Mesh:
Year: 2022 PMID: 35093012 PMCID: PMC8800405 DOI: 10.1186/s12879-022-07075-1
Source DB: PubMed Journal: BMC Infect Dis ISSN: 1471-2334 Impact factor: 3.090
Fig. 1Schematic illustration of virus intrusion (A), disease progression (B) and the implementation of surveillance (C). : Susceptible, : Exposed, : Presymptomatically Infectious, : Symptomatically Infectious, : Asysmptomatically Infectious, : Recovered. Panel C demonstrates symptom-based baseline surveillance in a hypothetical case scenario. Agent 1 has been infected outside of the clinic (index case) and infects agent 2, who goes on to infect agent 3 and 4. On day 6, agent 2 is isolated due to developing symptoms and once the case is ascertained a day later, contact tracing isolates the primary infector (backward tracing) and subsequent infections by agent 2 (forward tracing). The isolated individuals are then tested, confirming that agent 1 and agent 3 are infectious. Agent 4 is released as the infection is not yet detectable
Summary of the used model parameters and their uncertainties according to literature
| Name | Unit | Lower | Best | Upper | Description | Source |
|---|---|---|---|---|---|---|
| Asymptomatic fraction | [%] | 10 | 20 | 30 | Fraction of asymptomatic disease courses | [ |
| Asymptomatic infectivity | [%] | 40 | 70 | 100 | Infectiousness of asymptomatic individuals compared to symptomatic individuals | [ |
| False symptoms | [agents/day] | 0.5 | 1 | 2 | Average daily amount of non-COVID-19 related symptomatic individuals | Assumed |
| False traces | [agents] | 4 | 8 | 12 | Average amount of erroneously traced individuals assuming perfect tracing efficiency | Assumed |
| Heterogeneity modifier | [] | 2 | 4 | 6 | Scaling factor of infectivity in transmission matrix of high-risk/low-risk staff | Assumed |
| Incubation mean | [days] | 5 | 5.5 | 6 | Mean of incubation time | [ |
| Incubation SD | [days] | 2.1 | 2.3 | 2.5 | Standard deviation of incubation time | [ |
| Infectivity heterogeneity | [] | 1 | 1.5 | 1000 | Heterogeneity in individual infectivity: Shape parameter of the Gamma-distribution | Derived from [ |
| Isolation fraction | [%/day] | 50 | 70 | 90 | Fraction of symptomatic individuals isolated daily | Assumed |
| Outside infection | [] | 0.01 | 0.04 | 0.16 | Scaling factor of infection risk outside of clinic | Assumed |
| Peak infectiousness | [days] | − 1 | 1 | 3 | Time shift of peak infectiousness relative to symptom onset | [ |
| Prevalence | [%] | 0.005 | 0.02 | 0.08 | COVID-19 prevalence in population including non-confirmed cases | Assumed |
| R0 | [] | 1.5 | 3 | 5 | Average number of infections an individual causes inside of clinic | Assumed |
| Symptom mean | [days] | 3.5 | 5 | 6.5 | Mean of symptomatic infectious time | Derived from [ |
| Symptom SD | [days] | 1.1 | 1.5 | 1.9 | Standard deviation of symptomatic infectious time | Derived from [ |
| Test compliance | [%] | 60 | 80 | 100 | Fraction of individuals compliant with repeated surveillance testing | Assumed |
| Test sensitivity | [%] | 80 | 90 | 100 | Sensitivity of diagnostic test | Derived from [ |
| Test specificity | [%] | 98 | 99.5 | 100 | Specificity of diagnostic test | Assumed |
| Tracing fraction | [%] | 50 | 70 | 90 | Fraction of infections reconstructed by contact tracing | Assumed |
Upper and lower bounds are used for 1-way sensitivity analysis as they represent the existing lack of knowledge about these parameters. The term “derived from” indicates that input from the stated sources was not directly applicable in the model and required some form of subjective judgement and modification prior to the inclusion into the model
Fig. 2Illustration of randomized disease state retention times (A) and random sample of 20 infectivity profiles (B). Distributions of retention times for different disease states (A) correspond to the best guess parameters extracted from literature. Each infectivity profile (B) describes the time course of infectiousness of one random individual. The individual profiles differ in their onsets and infectivity levels
Fig. 3Reduction of outbreak probability by active testing strategies relative to the symptom-based baseline strategy. Results are illustrated on a log2-scale. The black lines correspond to the estimate of outbreak reduction for the best guess parameters. Each point corresponds to the estimated outbreak reduction for a 1-way sensitivity analysis of the corresponding parameter towards its upper bound (red) or lower bound (blue). Uncertainties due to stochasticity of the dynamics are visualized by 1 error bars. The results for the expected reduction of the outbreak probability are robust to most epidemiological parameter assumptions, the exact parameter values employed are stated in Table 1
Fig. 4Impact of test-to-result delay (A), definition of outbreak size (B) and compliance (C) on the relative outbreak probability. The vertical axes denote outbreak probabilities on a log 2-scale, normalized relative to the largest outbreak probability of the respective analysis. Uncertainties due to stochasticity of the dynamics are visualized by 1 error bars, but these are mostly smaller than the point size. Results correspond to the best guess parameter set (except for changes for the particular analysis). A Decreasing test-to-result delay leads to more effective surveillance. B Decreasing probabilities within a strategy implies containment of ongoing outbreaks. C Different levels of compliance are analysed for various regular testing frequencies implemented on top of the symptom-based baseline surveillance strategy and entry testing. The horizontal axis corresponds to a frequency scale, as test frequency is proportional to test resources required. Benefits of increasing the test frequency are limited by lack of compliance, especially if test frequency is already high